5 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow AlgiPharma AS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis OligoG Dry powder for inhalation - Cystic Fibrosis | Phase 2 / Phase 3 | Withdrawn | AlgiPharma AS | 2021-09-01 | 2022-06-30 | |
| A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis OligoG DPI - Cystic Fibrosis | Phase 2 | Terminated | AlgiPharma AS | 15 | 2019-05-16 | 2024-10-28 |
| A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection Alginate oligosaccharide, Placebo - Cystic Fibrosis, Burkholderia Infection | Phase 2 | Completed | AlgiPharma AS | 15 | 2015-02-01 | 2018-04-19 |
| A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis alginate oligosaccharide - Cystic Fibrosis | Phase 2 | Completed | AlgiPharma AS | 65 | 2014-10-01 | 2018-04-19 |
| A Study to Investigate Lung Deposition of Radiolabelled OligoG Radiolabelled OligoG CF-5/20 DPI, Radiolabelled OligoG CF-5/20 6% Solution - Cystic Fibrosis | Phase 2 | Completed | BDD Pharma Ltd | 10 | 2014-04-01 | 2015-02-09 |
| A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis OligoG CF-5/20, Saline - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | AlgiPharma AS | 26 | 2011-05-01 | 2015-01-14 |
| Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis OligoG CF-5/20 - Cystic Fibrosis | Phase 1 | Completed | AlgiPharma AS | 26 | 2009-09-01 | 2016-03-23 |
Cystic Fibrosis (7) · Burkholderia Infections (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Respiratory Tract Diseases (1)
oligoG CF-5-20 (4) · Inhalation (2) · Sodium Chloride (1) · Solutions (1)
United Kingdom (4) · Germany (3) · Australia (1) · Denmark (1) · Ireland (1) · Norway (1) · Sweden (1)
Howard NE Stevens, PhD (1) · Martin Walshaw, MD (1) · Peter Wark (1) · Rainald Fischer, MD, PD (1) · Salvatore Febbraro (1) · Silke van Koningsbruggen-Rietschel, MD, PhD (1) · Tacjana Pressler, PhD MD (1)
2018 (1)